clofibric acid has been researched along with Cardiovascular Diseases in 110 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids." | 4.84 | Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007) |
| "Statin treatment (and possibly niacin when given alone or in combination with statins) appears to be associated with a slightly increased risk of new onset diabetes mellitus (NODM)." | 3.76 | Lipid-lowering agents and new onset diabetes mellitus. ( Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K, 2010) |
| "Clofibric acid was only effective in reducing triglycerides." | 2.67 | Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. ( Dude, H; Fischer, S; Hanefeld, M; Julius, U; Rothe, G; Schmechel, H; Schulze, J; Schwanebeck, U, 1991) |
| "The evidence to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials pending." | 2.44 | Managing dyslipidemia in chronic kidney disease. ( Harper, CR; Jacobson, TA, 2008) |
| "Ursodeoxycholic acid the standard treatment of primary biliary cirrhosis improves the cholestasis and hereby lowers circulating levels of cholesterol." | 2.44 | Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated. ( Balmer, ML; Dufour, JF, 2008) |
| "Hypertriglyceridemia is a commonly encountered problem in primary care practice." | 2.44 | Bridging the gap in treatment options for patients with hypertriglyceridemia. ( Hays, R; Underberg, JA, 2007) |
| " Myopathy, liver enzyme elevations, and cholecystitis have been potential adverse reactions of interest." | 2.44 | Expert commentary: the safety of fibrates in lipid-lowering therapy. ( Brown, WV, 2007) |
| "Established treatments of dyslipidemias are statins and fibrates." | 2.44 | The treatment of dyslipidemia--what's left in the pipeline? ( Popescu, L; Rau, O; Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H, 2008) |
| "The metabolic syndrome is defined as a clustering of cardiovascular risk factors with insulin resistance, including dyslipidemia, coagulation disturbances and hypertension." | 2.44 | Measuring biomarkers to assess the therapeutic effects of PPAR agonists? ( Chinetti-Gbaguidi, G; Staels, B, 2007) |
| "Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL." | 2.44 | Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008) |
| "Thus, targeting the hyperglycemia in type 2 diabetes mellitus (DM) alone will not eliminate all of the excess cardiovascular risk; rather aggressive treatment is needed for all of the modifiable cardiometabolic risk factors." | 2.44 | Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. ( Gerich, JE, 2007) |
| "The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension." | 2.43 | Therapeutical effects of PPAR agonists assessed by biomarker modulation. ( Chinetti-Gbaguidi, G; Fruchart, JC; Staels, B, 2005) |
| "Treatment of HIV dyslipidemia should include lifestyle modifications such as a low-fat diet, increased exercise, reduced alcohol consumption and smoking cessation." | 2.43 | Strategies for management and treatment of dyslipidemia in HIV/AIDS. ( Sax, PE, 2006) |
| "The approach to the management of hyperlipidemia has evolved dramatically over the past decade." | 2.43 | Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. ( Balbisi, EA, 2006) |
| "Eight trials and 12 249 patients with type 2 diabetes were included in the analyses." | 2.43 | Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. ( Allemann, S; Christ, ER; Diem, P; Egger, M; Stettler, C, 2006) |
| "The metabolic syndrome is a clustering of risk factors including central obesity, insulin resistance, dyslipidaemia and hypertension." | 2.43 | Dyslipidaemia, hypercoagulability and the metabolic syndrome. ( Athyros, VG; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP, 2006) |
| "Atorvastatin has little or no ability to increase high density lipoprotein (HDL)-cholesterol, and this may be a disadvantage in patients with metabolic syndrome or diabetes, where low HDL-cholesterol is a key feature." | 2.43 | Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. ( Doggrell, SA, 2006) |
| "The metabolic syndrome is commonly encountered in the United States." | 2.42 | Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. ( Reasner, CA; Rosenson, RS, 2004) |
| "Although type 2 diabetes is associated with a clustering of risk factors, the cause for an excess risk of cardiovascular disease remains unknown." | 2.41 | Lipids in type 2 diabetes. ( Laakso, M, 2002) |
| "Ciprofibrate is an effective treatment for three main types of atherogenic hyperlipoproteinaemia: type IIa hypercholesterolaemia, type IIb combined hyperlipidaemia, and type IV hypertriglyceridaemia." | 2.39 | Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. ( Bruckert, E; Turpin, G, 1996) |
| "Niacin and fibrates have been shown in clinical trials to be effective as adjunctive therapy for these lipid abnormalities." | 1.35 | Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. ( Laitinen, D; Sullivan, JM; Toth, PP; Zarotsky, V, 2009) |
| "4%) achieved goal following treatment changes, including upward dosage adjustments." | 1.34 | Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. ( Márk, L; Ofner, P; Pados, G; Paragh, G; Zámolyi, K, 2007) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | 1.33 | [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (5.45) | 18.2507 |
| 2000's | 94 (85.45) | 29.6817 |
| 2010's | 10 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 2 |
| Codario, RA | 1 |
| Harper, CR | 1 |
| Jacobson, TA | 2 |
| Edavalath, M | 1 |
| Rees, A | 1 |
| Paragh, G | 2 |
| Harangi, M | 1 |
| László, M | 1 |
| Staels, B | 8 |
| Maes, M | 1 |
| Zambon, A | 2 |
| Balmer, ML | 1 |
| Dufour, JF | 1 |
| Underberg, JA | 1 |
| Hays, R | 1 |
| Gorkin, JU | 1 |
| Watson, K | 1 |
| Knopp, RH | 2 |
| White, CR | 1 |
| Datta, G | 1 |
| Zhang, Z | 1 |
| Gupta, H | 1 |
| Garber, DW | 1 |
| Mishra, VK | 1 |
| Palgunachari, MN | 1 |
| Handattu, SP | 1 |
| Chaddha, M | 1 |
| Anantharamaiah, GM | 1 |
| Marchiori, M | 1 |
| Manzato, E | 1 |
| Gandotra, P | 1 |
| Miller, M | 3 |
| Toth, PP | 2 |
| Rosenson, RS | 4 |
| Pitt, B | 1 |
| Hausenloy, DJ | 2 |
| Yellon, DM | 2 |
| Dominiczak, M | 1 |
| Cardenas, GA | 1 |
| Lavie, CJ | 1 |
| Cardenas, V | 1 |
| Milani, RV | 1 |
| McCullough, PA | 1 |
| Seth Loomba, R | 1 |
| Arora, R | 1 |
| Hughes, S | 1 |
| Ansquer, JC | 1 |
| Foucher, C | 1 |
| Aubonnet, P | 1 |
| Le Malicot, K | 1 |
| Nair, AP | 1 |
| Darrow, B | 1 |
| Montecucco, F | 1 |
| Mach, F | 1 |
| Saha, SA | 2 |
| Arora, RR | 2 |
| Avis, HJ | 1 |
| Vissers, MN | 1 |
| Wijburg, FA | 1 |
| Kastelein, JJ | 1 |
| Hutten, BA | 1 |
| Merkel, M | 1 |
| Wierzbicki, AS | 2 |
| Zarotsky, V | 1 |
| Sullivan, JM | 1 |
| Laitinen, D | 1 |
| Lahoz, C | 1 |
| Mostaza, JM | 1 |
| Drexel, H | 1 |
| Abourbih, S | 1 |
| Filion, KB | 1 |
| Joseph, L | 1 |
| Schiffrin, EL | 2 |
| Rinfret, S | 1 |
| Poirier, P | 1 |
| Pilote, L | 1 |
| Genest, J | 1 |
| Eisenberg, MJ | 1 |
| Ginsberg, HN | 1 |
| Maccallum, PR | 1 |
| Sharma, RK | 1 |
| Singh, VN | 1 |
| Reddy, HK | 1 |
| Januszewicz, A | 1 |
| Okopień, B | 1 |
| Haberka, M | 1 |
| Sierant, M | 1 |
| Fiévet, C | 1 |
| Nakajima, K | 1 |
| Jun, M | 1 |
| Foote, C | 1 |
| Lv, J | 1 |
| Neal, B | 1 |
| Patel, A | 1 |
| Nicholls, SJ | 1 |
| Grobbee, DE | 1 |
| Cass, A | 1 |
| Chalmers, J | 1 |
| Perkovic, V | 1 |
| Athyros, VG | 2 |
| Tziomalos, K | 1 |
| Karagiannis, A | 2 |
| Mikhailidis, DP | 4 |
| Ruiz, J | 1 |
| Delanaye, P | 1 |
| Scheen, AJ | 1 |
| Braillon, A | 1 |
| Rubenfire, M | 1 |
| Brook, RD | 1 |
| Kostoula, A | 1 |
| Elisaf, M | 1 |
| Robins, SJ | 2 |
| Jonkers, IJ | 1 |
| Smelt, AH | 1 |
| van der Laarse, A | 1 |
| Reasner, CA | 1 |
| Khera, A | 1 |
| McGuire, DK | 1 |
| Hanefeld, M | 2 |
| Studer, M | 1 |
| Leimenstoll, B | 1 |
| Glass, TR | 1 |
| Bucher, HC | 1 |
| Mosca, L | 1 |
| Meyers, CD | 1 |
| Kashyap, ML | 1 |
| Chapman, MJ | 2 |
| Fruchart, JC | 3 |
| Chinetti-Gbaguidi, G | 3 |
| Kon, YC | 1 |
| Laakso, M | 2 |
| Han, SH | 1 |
| Quon, MJ | 1 |
| Koh, KK | 1 |
| Gouni-Berthold, I | 2 |
| Krone, W | 2 |
| Thompson, MM | 1 |
| Reed, SC | 1 |
| Cockerill, GW | 1 |
| Sax, PE | 1 |
| Rizzo, M | 1 |
| Berneis, K | 1 |
| Balbisi, EA | 1 |
| Jancsó, Z | 1 |
| Varga, Z | 1 |
| Simay, A | 1 |
| Ilyés, I | 1 |
| Barter, PJ | 2 |
| Rye, KA | 2 |
| Allemann, S | 1 |
| Diem, P | 1 |
| Egger, M | 1 |
| Christ, ER | 1 |
| Stettler, C | 1 |
| Charlton-Menys, V | 1 |
| Durrington, P | 1 |
| Roberts, BH | 1 |
| Thompson, PD | 1 |
| Touyz, RM | 1 |
| Bloomfield, HE | 1 |
| Kakafika, AI | 1 |
| Liberopoulos, EN | 1 |
| Konstantinov, VO | 1 |
| Saĭfulina, IaR | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Howard, PA | 1 |
| Brown, WV | 1 |
| Taskinen, MR | 1 |
| Moulin, P | 1 |
| Keidar, S | 1 |
| Guttmann, H | 1 |
| Stam, T | 1 |
| Fishman, I | 1 |
| Shapira, C | 1 |
| Schaefer, EJ | 1 |
| Márk, L | 1 |
| Zámolyi, K | 1 |
| Pados, G | 1 |
| Ofner, P | 1 |
| Miyauchi, K | 1 |
| Benatar, JR | 1 |
| Stewart, RA | 1 |
| Ballantyne, CM | 1 |
| Rau, O | 1 |
| Zettl, H | 1 |
| Popescu, L | 1 |
| Steinhilber, D | 1 |
| Schubert-Zsilavecz, M | 1 |
| Kizhakepunnur, LG | 1 |
| Bahekar, A | 1 |
| Davidson, MH | 1 |
| Usman, M | 1 |
| Peter, R | 1 |
| Kuusisto, J | 1 |
| Andrulionyte, L | 1 |
| Dupuy, AM | 1 |
| Carrière, I | 1 |
| Scali, J | 1 |
| Cristol, JP | 1 |
| Ritchie, K | 1 |
| Dartigues, JF | 1 |
| Gambert, P | 1 |
| Ancelin, ML | 1 |
| Fazio, S | 1 |
| Brinton, EA | 1 |
| Paramsothy, P | 1 |
| Atkinson, B | 1 |
| Dowdy, A | 1 |
| Brown, BG | 1 |
| Zhao, XQ | 1 |
| Paumelle, R | 1 |
| Gerich, JE | 1 |
| Doggrell, SA | 1 |
| Bruckert, E | 2 |
| Turpin, G | 1 |
| Ganotakis, ES | 2 |
| Spyropoulos, KA | 1 |
| Jagroop, IA | 2 |
| Byrne, DJ | 1 |
| Winder, AF | 2 |
| Papadakis, JA | 1 |
| Watts, GF | 1 |
| Dimmitt, SB | 1 |
| Wright, JM | 1 |
| Puil, L | 1 |
| Bassett, CL | 1 |
| Fischer, S | 1 |
| Schmechel, H | 1 |
| Rothe, G | 1 |
| Schulze, J | 1 |
| Dude, H | 1 |
| Schwanebeck, U | 1 |
| Julius, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers[NCT01148004] | Phase 1 | 25 participants (Actual) | Interventional | 2010-05-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
84 reviews available for clofibric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Managing dyslipidemia in chronic kidney disease.
Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty | 2008 |
[New trends in lipidology: the increasing role of HDL-cholesterol].
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Pr | 2008 |
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; D | 2008 |
Treatment of hypercholesterolemia in patients with primary biliary cirrhosis might be more beneficial than indicated.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2008 |
Bridging the gap in treatment options for patients with hypertriglyceridemia.
Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Comorbidity; Drug Monitoring; Drug | 2007 |
Strategies for reducing cardiovascular risk in patients with hypertriglyceridemia.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Exercise; Fa | 2007 |
HDL therapy for cardiovascular diseases: the road to HDL mimetics.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Pr | 2008 |
The role of triglycerides in cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Humans; Hypertriglyceridemia; | 2008 |
When high is low: raising low levels of high-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; | 2008 |
Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Topics: Antioxidants; Apolipoprotein A-I; Apoptosis; ATP Binding Cassette Transporter 1; ATP Binding Cassett | 2008 |
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; C | 2008 |
Fibrates: where are we now?
Topics: C-Reactive Protein; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemia | 2009 |
Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; | 2009 |
Lipid management in the geriatric patient.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Coronary Disea | 2009 |
Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Li | 2010 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Chole | 2009 |
[Diabetic dyslipoproteinemia: beyond LDL].
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy | 2009 |
Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Creatinine; Diabetes Me | 2009 |
[HDL-cholesterol: from risk factor to therapeutic target].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypercholesterolemia; Niacin; Ris | 2009 |
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2009 |
Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
Topics: Anion Exchange Resins; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Fatty Acid | 2009 |
Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.
Topics: Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Fe | 2009 |
The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dysli | 2009 |
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therap | 2009 |
[Influence of ACE inhibitors and fibrates on endothelial function].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cardiovascular Diseases; Clofibr | 2005 |
[Pleiotropic action of ACE-I and fibrates].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipid | 2005 |
Combination therapy of statins and fibrates in the management of cardiovascular risk.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Humans; Hydrox | 2009 |
Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type | 2010 |
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hypolipidemic Agents; Randomized Controlled Trials | 2010 |
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combinatio | 2010 |
Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?
Topics: Anticholesteremic Agents; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; | 2003 |
Hypertriglyceridemia: associated risks and effect of drug treatment.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Feeding Behavior; Fish Oil | 2001 |
Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-Co | 2004 |
Management of diabetic dyslipidemia: need for reappraisal of the goals.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Complications; Drug Therapy, Combination; Dyslipid | 2005 |
Outcome studies in type 2 diabetes.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Diabetes M | 2005 |
Effect of different antilipidemic agents and diets on mortality: a systematic review.
Topics: Cardiovascular Diseases; Clofibric Acid; Diet, Fat-Restricted; Fatty Acids, Omega-3; Humans; Hydroxy | 2005 |
Management of dyslipidemia in women in the post-hormone therapy era.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Die | 2005 |
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Topics: Amides; Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cho | 2005 |
Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Humans; Hydrox | 2005 |
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Inflamm | 2005 |
Pleiotropic effects of fibrates.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hypolipidemic Agents; PPAR | 2005 |
Lipids in type 2 diabetes.
Topics: Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; H | 2002 |
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Topics: Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Huma | 2005 |
Hypertriglyceridemia-why, when and how should it be treated?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Comorbidity; Evidence-Based Medic | 2005 |
Therapeutic approaches to raising plasma HDL-cholesterol levels.
Topics: Animals; Cardiotonic Agents; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer P | 2004 |
Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Clofibric Acid; Humans; Inflammation; | 2005 |
Strategies for management and treatment of dyslipidemia in HIV/AIDS.
Topics: Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Clofibric Acid; Drug Interactions; H | 2006 |
Low-density lipoprotein size and cardiovascular risk assessment.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2006 |
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Th | 2006 |
Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
Topics: Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; | 2006 |
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Ra | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovas | 2006 |
Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Clofi | 2006 |
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Endothelium, Vascular; | 2006 |
Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Randomized Controlled Trials as Topic | 2006 |
Dyslipidaemia, hypercoagulability and the metabolic syndrome.
Topics: Adipose Tissue; Adiposity; Animals; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Ac | 2006 |
[Favorable effects of decreasing lipids in patients with diabetes mellitus].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2006 |
Fibrates after the FIELD study: Some answers, more questions.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-Co | 2006 |
[Cardiovascular risk and possibilities of lowering it in patients with metabolic syndrome and type II diabetes mellitus. The role of fibrates].
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Humans; Hypolipidemic Agents; Me | 2006 |
Optimal lipid modification: the rationale for combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as | 2005 |
Expert commentary: the safety of fibrates in lipid-lowering therapy.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Databases, Factual; Dyslipidemias | 2007 |
Hypertriglyceridemia and cardiovascular risk reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu | 2007 |
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Humans; Hypertriglyceridemia; Hypolipidem | 2008 |
[Role of fibrate in cardiovascular disease prevention].
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hyperlipidemias | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Dia | 2007 |
Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty Acids, Omega-3; Humans; Hydroxymethylg | 2007 |
The treatment of dyslipidemia--what's left in the pipeline?
Topics: Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cl | 2008 |
The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.
Topics: Cardiovascular Diseases; Clofibric Acid; Follow-Up Studies; Humans; Hypolipidemic Agents; Randomized | 2007 |
Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylgluta | 2007 |
Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Topics: Animals; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Meta | 2007 |
Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Clofib | 2007 |
Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Topics: Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Me | 2008 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol | 2008 |
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci | 2008 |
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
Topics: Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase | 2008 |
Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Artery Disease; Diabetes Complications; Diabetes M | 2007 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Tr | 2006 |
The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
Topics: Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agents | 1996 |
Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
Topics: Animals; Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hyperlipoproteinemias; Hypol | 1996 |
Fibrates, dyslipoproteinaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clin | 1999 |
Analysis of serious adverse events. Lipid-lowering therapy revisited.
Topics: Cardiovascular Diseases; Clofibric Acid; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; | 2002 |
2 trials available for clofibric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Field of confusion: future prospects for fibrate therapy in cardiovascular disease.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Diabetes Mellitus, Type 2; Double-Blind | 2006 |
Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Diabeti | 1991 |
24 other studies available for clofibric acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Hypertriglyceridemia and cardiovascular disease management.
Topics: Adult; Cardiovascular Diseases; Clofibric Acid; Disease Management; Fatty Acids, Omega-3; Female; Hu | 2007 |
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management.
Topics: Adult; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Humans; Hydroxymethylgluta | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases | 2008 |
Triglycerides and cardiovascular events in ACS: the need for combined lipid-altering therapies.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clofibric Acid; Drug Therapy, Combination; Humans; | 2009 |
Hyperlipidaemia and cardiovascular disease: nonlipid-lowering effects of omega-3 fatty acids, statins and fibrates.
Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Fatty Acids, Omega-3; Femal | 2009 |
On the road to better dyslipidemia outcomes.
Topics: Azetidines; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Ezetimibe; Fish Oils; Humans; Hy | 2009 |
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Drug Combinations; Female; Humans; | 2009 |
Dyslipidemia and cardiovascular risk: the importance of early prevention.
Topics: Cardiovascular Diseases; Clofibric Acid; Drug Combinations; Dyslipidemias; Fatty Acids, Omega-3; Hum | 2009 |
Lipid-lowering agents and new onset diabetes mellitus.
Topics: Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus; Dyslipidemias; Evidence-Based Medicine; | 2010 |
Fibrates in CVD: a step towards personalised medicine.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2010 |
[On behalf and the extent of evidence].
Topics: Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, | 2010 |
Effects of fibrates on cardiovascular outcomes.
Topics: Biomarkers; Cardiovascular Diseases; Clofibric Acid; Creatinine; Humans; Hypolipidemic Agents; Meta- | 2010 |
Effects of fibrates on cardiovascular outcomes.
Topics: Cardiovascular Diseases; Clofibric Acid; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Risk | 2010 |
Fibrates and C-reactive protein.
Topics: C-Reactive Protein; Cardiovascular Diseases; Clofibric Acid; Fibric Acids; Humans; Hydroxymethylglut | 2003 |
High-density lipoprotein cholesterol: ready for prime time?
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ch | 2005 |
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity | 2005 |
The role of PPAR-alpha agonists in the prevention of CVD in diabetes.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type | 2007 |
[Metabolically designed treatments: from biochemistry to the vessel lining].
Topics: Biguanides; Cardiovascular Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglu | 2007 |
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Di | 2007 |
Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Cost-Benefit A | 2007 |
Fibrate therapy: safety considerations.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA | 2007 |
Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Clofibric Acid; Drug Therapy, Combina | 2008 |
Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
Topics: Body Weight; Cardiovascular Diseases; Clofibric Acid; Female; Fibric Acids; Fibrinogen; Humans; Hype | 1998 |
Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Clof | 1999 |